{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:25:40Z","timestamp":1771043140835,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.cgh.2015.05.022","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T15:59:18Z","timestamp":1436371158000},"page":"1919-1925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn\u2019s Disease and Effects of Natalizumab Therapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Emanuelle","family":"Bellaguarda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian","family":"Keyashian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Pekow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2015.05.022_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2015.05.022_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00535-005-1744-3","article-title":"Novel pathophysiological concepts of inflammatory bowel disease","volume":"41","author":"Hibi","year":"2006","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2015.05.022_bib3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1053\/j.gastro.2009.07.049","article-title":"Th1\/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease","volume":"137","author":"Sakuraba","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2015.05.022_bib4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12","author":"Hanauer","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2015.05.022_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2015.05.022_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2015.05.022_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2015.05.022_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00384-011-1398-y","article-title":"The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study","volume":"27","author":"Sakuraba","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.cgh.2015.05.022_bib9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib11","first-page":"144","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus\/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA","volume":"2","author":"Tyler","year":"2005","journal-title":"Rev Neurol Dis"},{"key":"10.1016\/j.cgh.2015.05.022_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Linda","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.cgh.2015.05.022_bib15","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.cgh.2015.05.022_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2013.11.031","article-title":"JCV epidemiology in MS (JEMS)\u2013epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients\u2013Portuguese data","volume":"337","author":"da Silva","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.cgh.2015.05.022_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A\u00a0second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cgh.2015.05.022_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MIB.0b013e31827eea78","article-title":"Natalizumab in Crohn's Disease: results from a US tertiary inflammatory bowel disease center","volume":"19","author":"Sakuraba","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2015.05.022_bib20","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1097\/MIB.0b013e3182a8df32","article-title":"Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease","volume":"19","author":"Sakuraba","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2015.05.022_bib21","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1097\/MIB.0b013e3182a32a0d","article-title":"Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals","volume":"19","author":"Juillerat","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2015.05.022_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cgh.2015.05.022_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ana.24148","article-title":"JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis","volume":"75","author":"Chalkias","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cgh.2015.05.022_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cgh.2015.05.022_bib25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1348-0421.1982.tb00254.x","article-title":"Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera","volume":"26","author":"Taguchi","year":"1982","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.cgh.2015.05.022_bib26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jmv.10436","article-title":"Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China","volume":"70","author":"Gu","year":"2003","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cgh.2015.05.022_bib27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1017\/cjn.2014.32","article-title":"Anti-JC virus antibody prevalence in Canadian MS patients","volume":"41","author":"Bhan","year":"2014","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.cgh.2015.05.022_bib28","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.cgh.2015.05.022_bib29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/gut.2007.145698","article-title":"JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?","volume":"57","author":"Verbeeck","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2015.05.022_bib30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.022_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515006989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515006989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:18:46Z","timestamp":1761542326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356515006989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1542356515006989"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2015.05.022","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn\u2019s Disease and Effects of Natalizumab Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2015.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}